Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Melanoma stories

Oct 22, 2026

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00
May 4, 2026

FDA Rejects Promising Melanoma Drug RP1 Twice, Raising Concerns About Drug Approval Process

The FDA has rejected RP1, a breakthrough melanoma treatment, twice despite its promise in treating skin cancer. The rejections have left medical professionals puzzled and concerned about implications for future drug approvals.

May 4, 2026·1 source
00

Top claims

  • ▪Trial leader Georgina Long stated that the combination therapy of Intismeran and pembrolizumab did not cause any major harmful side effects among participants
  • ▪Oncologist Georgina Long noted that nearly 55% of people with advanced melanoma are now cured with targeted drugs or immunotherapies, compared to survival measured in months 15 years ago
  • ▪BMO Capital Markets analyst Evan Seigerman stated that Moderna's stock price drop reflected inflated market expectations rather than a true indictment of the Intismeran and Keytruda combination therapy's efficacy

Topics

Cancer & OncologyCancer TypesClinical trialsCancer immunotherapyMRNA vaccine technologyPersonalized medicineCancerCancer treatment breakthroughsOncologyCancer treatmentDrug Policy, Pricing & ApprovalDrug approval processNew drug application (NDA) processFDA drug approval processHealthcare PolicyDrug Approval and Clinical Trials

Related entities

MerckUnited States